Pyrotinib Boosts Survival in HER2+ Metastatic Breast Cancer
Patients treated with pyrotinib plus capecitabine survived longer than those treated with lapatinib plus capecitabine in the PHOEBE trial.
Medscape Medical News
source https://www.medscape.com/viewarticle/965253?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/965253?src=rss
Comments
Post a Comment